Rosuvastatin in patients with acute coronary syndrome sCD40L MMP2 and hsCRP of.doc

 PAGE \* MERGEFORMAT 10 Rosuvastatin in patients with acute coronary syndrome sCD40L MMP2 and hsCRP of [Abstract] Objective rosuvastatin (rosuvastatin) with acute coronary syndrome (ACS) patients with sCD40L, MMP 2 hs CRP. Methods 61 patients selected ACS, stable angina (SA) 19 patients and normal control group of 30 patients. ACS were randomly divided into the rosuvastatin group (33 cases) and routine treatment group (28 cases) were compared among the groups of serum sCD40L MMP 2 and hs CRP levels. Results ACS Group with the SA group and normal control group serum sCD40L MMP 2 and hs CRP levels significantly compared to the two treatment groups after treatment, serum sCD40L MMP 2, and hs CRP levels significantly compared. Conclusion Ruishu ACS atorvastatin can reduce the serum sCD40L MMP 2 and hs CRP levels, reduce the degradation of matrix components of coronary atherosclerotic plaque and inflammation, which play a stabilizing atherosclerotic plaque. [Keywords:] acute coronary syndrome; matrix metalloproteinase-2; soluble CD40 ligand; high-sensitivity C-reactive protein; rosuvastatin Coronary plaque instability leading to acute coronary syndrome (ACS) plaque rupture and thrombosis of the direct cause. MMPs is the role of the powerful protease system, almost all biodegradable extracellular matrix (ECM), its spot block the activity increased to increase the degradation of matrix components, thereby reducing plaque stability, promote the formation of vulnerable plaque, which led to the occurrence of ACS. MMP 2 specifically degrade collagen and basement membrane matrix components in the plaque play a major role in the degradation. sCD40L levels and the occurrence of ACS. hs CRP is the inflammatory response in the body tag can be used as markers of vascular inflammation is an independent risk factor for cardiovascular disease. In this study, a randomized, controlled approach In ACS patients with rosuvastatin before and after treatment, serum sCD40L, MMP 2